LDL Cholesterol Targets Across Cardiovascular Risk Categories

Definition and pathophysiology

Low-density lipoprotein cholesterol (LDL-C) is the principal therapeutic target in lipid management because LDL and other apolipoprotein B-containing lipoproteins play a causal role in atherosclerotic cardiovascular disease (ASCVD). This causal relationship is supported by genetic, observational and interventional evidence.

The relationship between LDL-C exposure and ASCVD risk is characterized by several principles:

• Lower LDL-C is associated with lower ASCVD risk across the range studied, including concentrations below 1.4 mmol/L (55 mg/dL).

• The proportional reduction in cardiovascular risk is related to the absolute reduction in LDL-C, regardless of the drug used to achieve it.

• Absolute benefit depends on baseline cardiovascular risk and the magnitude of LDL-C reduction. Thus, even a modest absolute reduction may be clinically important in individuals at high or very high risk.

• Prolonged exposure to lower LDL-C concentrations is associated with lower ASCVD risk.

Atherogenic particle burden is not completely represented by LDL-C alone. Non-high-density lipoprotein cholesterol (non-HDL-C) includes cholesterol carried by LDL, intermediate-density lipoprotein, lipoprotein(a), very-low-density lipoprotein and chylomicron remnants. It is calculated as:

Non-HDL-C = total cholesterol − HDL-C

Apolipoprotein B (apoB) reflects the concentration of circulating atherogenic particles because each apoB-containing particle carries one apoB molecule. LDL-C, non-HDL-C and apoB are usually correlated, but discordance may occur when particles differ in cholesterol content or size. In such cases, cardiovascular risk may track more closely with apoB than with LDL-C or non-HDL-C, particularly in patients with metabolic syndrome or elevated triglycerides despite normal or low LDL-C.

HDL cholesterol (HDL-C) is inversely associated with cardiovascular risk in observational studies, but it is not a validated treatment target. Raising HDL-C pharmacologically has not been shown to reduce cardiovascular events. Very high HDL-C may paradoxically be associated with increased risk, and HDL-C should therefore be interpreted as a risk-assessment variable rather than a therapeutic objective.

LDL-C as the primary treatment target

Current lipid-management frameworks place LDL-C at the centre of treatment. Lifestyle intervention is foundational, but pharmacological LDL-C lowering is required when cardiovascular risk is sufficiently high or when LDL-C is markedly elevated.

Non-HDL-C and apoB are secondary targets or risk-refining measures, particularly in patients with:

• Diabetes or other cardiometabolic risk factors

• Obesity

• Insulin resistance or metabolic syndrome

• Elevated triglycerides

• Low or apparently well-controlled LDL-C with suspected residual atherogenic particle burden

In patients with diabetes and combined dyslipidaemia, non-HDL-C is particularly relevant because it captures triglyceride-rich lipoproteins in addition to LDL and other apoB-containing particles.

Cardiovascular risk categories

Primary prevention

For adults aged 40–75 years without diabetes and with LDL-C between 70 and 189 mg/dL, 10-year risk of a first hard ASCVD event—fatal or nonfatal myocardial infarction or stroke—should be estimated.

The risk categories are:

Management should incorporate the estimated risk, risk-enhancing factors and a clinician–patient discussion regarding the expected net benefit of therapy. Lifestyle modification is appropriate across the risk spectrum. Statin therapy is considered when the anticipated benefit is sufficient, with coronary artery calcium (CAC) scoring used when treatment decisions remain uncertain.

Secondary prevention

Individuals with established clinical ASCVD require LDL-C lowering to reduce recurrent major cardiovascular events, including myocardial infarction, stroke, peripheral arterial disease events and mortality. The cited prevention guidance recommends statin therapy producing a 30%–49% LDL-C reduction in adults with CVD regardless of age.

The source material does not provide a complete numerical LDL-C target table for each secondary-prevention risk stratum. It does, however, support more intensive LDL-C lowering in patients at higher absolute risk and the use of additional LDL-C-lowering therapies when statins alone are insufficient or not tolerated.

Diabetes mellitus

LDL-C remains the primary lipid target in diabetes. Treatment targets differ according to cardiovascular risk, although the source material does not specify the numerical LDL-C thresholds for each diabetes-risk category. Non-HDL-C should also be considered in patients with diabetes and combined dyslipidaemia.

No clear recommendation is provided for lipid targets in type 2 diabetes at low cardiovascular risk because of limited evidence.

Familial hypercholesterolaemia and genetic lipid disorders

The SCORE2 algorithm is not intended for patients with a genetic lipid disorder such as familial hypercholesterolaemia. In such individuals, specific LDL-C thresholds and treatment targets are applied irrespective of estimated global cardiovascular risk.

The supplied material does not specify the numerical LDL-C targets for familial hypercholesterolaemia.

Older adults

LDL-C and total cholesterol may plateau or decline with age, and the association between LDL-C and cardiovascular events becomes weaker. Nevertheless, LDL-C remains associated with fatal cardiovascular events in adults aged 65 years and older.

For secondary prevention, statin therapy is recommended to lower LDL-C by 30%–49% regardless of age. In primary prevention, treatment decisions in older adults should account for future cardiovascular risk and the uncertainty introduced by the strong influence of age in pooled cohort risk equations. A CAC score of zero indicates relatively low risk at all ages, although elevated CAC is less prognostic in older than in younger adults.

The 2018 guideline provides a Class IIb recommendation for statin therapy as primary prevention in older adults. Evidence from clinical trials is more limited in the very old, particularly those aged 80 years or more.

Risk refinement when the treatment decision is uncertain

Coronary artery calcium

CAC scoring can refine risk classification in adults for whom the decision to initiate or intensify statin therapy is uncertain. Individuals with elevated CAC have higher cardiovascular risk, and management should address all modifiable risk factors through lifestyle and pharmacological treatment.

Most patients with CAC and a baseline 10-year ASCVD risk above 5% have a sufficiently high estimated risk to benefit from lipid-lowering therapy. Moderate-to-severe CAC should prompt consideration of high-intensity statin therapy.

A CAC score above 300 identifies a group with risk comparable to patients with established coronary heart disease and may support treatment approaches generally used for secondary prevention. CAC above 400 has been used as an entry criterion in cardiovascular outcome studies and in trials assessing novel lipid-related therapies.

In asymptomatic individuals with severe CAC, preventive treatment is generally preferred to routine downstream invasive assessment. Additional exercise testing may be reasonable when symptoms or exercise capacity are uncertain. Invasive coronary angiography should not be performed solely because an asymptomatic individual has severe CAC. Even with CAC above 1000, significant ischaemia is detected in only approximately 15% of patients.

Lipoprotein(a)

Lipoprotein(a) [Lp(a)] contributes causally to ASCVD and aortic valve stenosis. Its concentration is predominantly genetically determined, with more than 90% of variation attributed to genetic factors, and levels vary among ethnic groups.

Risk begins to rise slightly at approximately 30 mg/dL (62 nmol/L) to 50 mg/dL (105 nmol/L) and becomes clinically relevant above 50 mg/dL (105 nmol/L). Higher concentrations are associated with progressively greater cardiovascular risk. The greatest associations are described for myocardial infarction and aortic valve stenosis, with weaker associations for peripheral arterial disease and heart failure.

Lp(a) should be measured at least once during adult life. Measurement is particularly useful in:

• Younger patients with familial hypercholesterolaemia

• Premature ASCVD without another clear risk factor

• A family history of premature ASCVD or high Lp(a)

• Individuals at moderate risk

• Patients close to a treatment decision threshold

A second measurement may be reasonable after menopause if the premenopausal value was borderline, because Lp(a) may increase after menopause. Molar measurement in nmol/L is preferred, although mg/dL remains clinically usable because assays vary substantially.

Specific Lp(a)-lowering therapy has not yet been shown to reduce ASCVD events or slow aortic stenosis. Until such evidence is available, elevated Lp(a) should prompt intensive management of conventional risk factors, including more intensive LDL-C lowering according to overall cardiovascular risk.

Polygenic coronary artery disease risk

A high coronary artery disease polygenic risk score has been associated with greater absolute and relative benefit from statins in primary prevention and from PCSK9 monoclonal antibody therapy in secondary prevention, even when LDL-C is only mildly elevated. It may assist prognostication and identify patients more likely to benefit from LDL-C-lowering treatment, although genotype-guided prospective trials are still needed.

LDL-C targets and corresponding treatment intensity

The supplied material establishes the principle that LDL-C lowering should be progressively intensified as cardiovascular risk increases, but it does not provide a complete numerical target table for low-, moderate-, high- and very-high-risk categories.

The available target-related information is summarized below:

Treatment and management

Lifestyle measures

Lifestyle intervention is the basis of lipid management and should accompany pharmacological therapy. The available material identifies the following population-level factors as relevant to lipid levels:

• Dietary fat intake, particularly fats from animal products and processed vegetable oils

• Physical inactivity

• Urbanization-associated lifestyle change

• Obesity

• Diabetes and other metabolic risk factors

The source material does not specify a detailed dietary prescription, exercise programme or weight-loss target.

Statins

Statins are the principal pharmacological treatment for LDL-C reduction. They are used:

• In secondary prevention

• In primary prevention when estimated risk and risk-enhancing features indicate sufficient expected benefit

• In patients with diabetes when cardiovascular risk supports treatment

• In patients with familial hypercholesterolaemia or other genetic lipid disorders

• In patients with elevated Lp(a) when overall cardiovascular risk warrants intensive LDL-C lowering

In secondary prevention, the cited guidance recommends an LDL-C reduction of 30%–49% regardless of age. The supplied material does not state individual statin names, doses or specific percentage reductions associated with particular regimens.

Statin-associated myalgia is the most common adverse effect. It occurs in up to 10% of patients in clinical practice, although reported rates are much lower in clinical trials. When symptoms occur, management may include dose adjustment or switching to another statin.

A small Lp(a)-raising effect has been suggested in some small studies, but individual-level data from seven randomized placebo-controlled statin outcome trials found no effect of statins on Lp(a) concentrations. Elevated Lp(a) should therefore not be used as a reason to withhold a clinically indicated statin.

Ezetimibe

Ezetimibe is an evidence-based addition to statin therapy. It is particularly useful in older patients who are statin-intolerant or who do not reach the required LDL-C level with the maximally tolerated statin dose.

The source material does not provide an ezetimibe dose or a numerical LDL-C reduction.

PCSK9 inhibitors

PCSK9 inhibition is another option when guideline-recommended LDL-C levels are not achieved with maximally tolerated statin therapy, including in older patients. PCSK9 monoclonal antibody therapy has also shown greater absolute and relative benefit among individuals with high polygenic coronary artery disease risk in secondary prevention analyses.

PCSK9 inhibitors lower Lp(a), but the source material does not establish that this reduction independently improves clinical outcomes. It also does not provide drug names, doses or administration schedules.

Bempedoic acid

Bempedoic acid is identified as an evidence-based alternative or addition to statins, ezetimibe and PCSK9 inhibitors for LDL-C lowering. The supplied material does not provide dosing, efficacy percentages or practical prescribing details.

Therapies under development

Several novel approaches to lipid metabolism are in development. Specific Lp(a)-directed injectable RNA therapies targeting apolipoprotein(a) production have reduced Lp(a) concentrations by 80%–98% in clinical investigations. Oral small-molecule and small-interfering-RNA approaches are also under study.

These therapies remain investigational in the supplied material, and their effect on ASCVD events or aortic valve stenosis has not yet been established.

Non-HDL-C and apoB in treatment assessment

Non-HDL-C is calculated from a routine lipid profile and captures cholesterol in all apoB-containing particles. It is especially informative in patients with elevated triglycerides or cardiometabolic disease. Treatment goals for non-HDL-C are generally approximately 30 mg/dL higher than corresponding LDL-C goals because triglyceride-rich lipoprotein cholesterol contributes to the measurement.

ApoB measures the number of atherogenic particles rather than their cholesterol content. It may be more closely related to cardiovascular risk than LDL-C when discordance exists, particularly in patients with metabolic abnormalities and normal or low LDL-C.

The 2019 European guidance recognizes LDL-C as the primary target and non-HDL-C and apoB as secondary treatment targets, especially when cardiometabolic risk factors are present or LDL-C is low. The 2018 and 2019 American guidance identifies apoB ≥130 mg/dL and non-HDL-C ≥190 mg/dL as risk-enhancing factors that can influence statin decisions in borderline- or intermediate-risk primary prevention. ApoB testing is particularly suggested when triglycerides are ≥200 mg/dL.

Guideline recommendations

The following recommendations are supported by the supplied guidance:

• Use LDL-C as the primary target of lipid-lowering therapy.

• Implement lifestyle measures in all patients, with pharmacological treatment added according to cardiovascular risk and LDL-C level.

• In established ASCVD, use statin therapy to achieve an LDL-C reduction of 30%–49% regardless of age.

• Consider ezetimibe when statin intolerance limits therapy or when the LDL-C level remains above the required level on the maximally tolerated statin dose.

• Consider PCSK9 inhibition when LDL-C goals are not achieved despite maximally tolerated therapy.

• Use non-HDL-C and apoB as secondary targets or risk-refining measures, particularly in patients with diabetes, obesity, elevated triglycerides, insulin resistance or metabolic syndrome.

• Estimate 10-year ASCVD risk in adults aged 40–75 years without diabetes and with LDL-C 70–189 mg/dL.

• Use CAC scoring when uncertainty remains about initiating or intensifying statin therapy.

• Consider high-intensity statins in moderate-to-severe CAC, and recognize CAC above 300 as a marker of risk comparable to established coronary heart disease.

• Measure Lp(a) at least once during adulthood, with particular emphasis on patients with premature ASCVD, familial hypercholesterolaemia, relevant family history or intermediate treatment decisions.

• Treat elevated Lp(a) through intensified management of established risk factors, especially LDL-C, because outcome benefits from specific Lp(a)-lowering therapies have not yet been demonstrated.

• Do not target HDL-C pharmacologically, because increasing HDL-C has not reduced cardiovascular events.

Prognosis and follow-up

Lowering LDL-C reduces cardiovascular risk in proportion to the absolute LDL-C reduction, with greater absolute benefit in patients at higher baseline risk. This principle supports more intensive treatment in established ASCVD, severe CAC, familial hypercholesterolaemia and other high-risk states.

Follow-up should assess:

• Response of LDL-C to treatment

• Achievement of the intended degree of LDL-C lowering

• Adherence to lifestyle and pharmacological therapy

• Statin-associated symptoms and tolerability

• The need for treatment intensification with ezetimibe, PCSK9 inhibition or bempedoic acid

• Non-HDL-C or apoB when triglycerides or cardiometabolic risk factors make LDL-C potentially misleading

• Lp(a) when its measurement is clinically indicated

The supplied material does not specify treatment-monitoring intervals or a detailed biochemical follow-up schedule.